Pfizer: Underappreciated Growth Story Driven by Oncology, Obesity Pipeline, and Post-LOE Recovery Prospects

Analyst Evan Seigerman from BMO Capital maintained a Buy rating on Pfizer and keeping the price target at $30.00.

Evan Seigerman has given his Buy rating due to a combination of factors that, in his view, position Pfizer for underappreciated growth and value creation versus its U.S. biopharma peers. He highlights management’s clear roadmap for 2026 and beyond, including a defined set of clinical and regulatory catalysts, particularly in oncology, where upcoming data readouts and potential label expansions for assets like Padcev and other Seagen-derived programs could materially expand Pfizer’s addressable markets. He also points to Pfizer’s growing obesity and metabolic franchise, strengthened by the Metsera transaction and the in-licensing of YaoPharma’s oral GLP-1, which together create a diversified platform across multiple targets and modalities, with management working to accelerate timelines toward a potential 2028 launch.
In addition, Seigerman underscores that Pfizer is actively planning for and through its loss-of-exclusivity period, with confidence that its pipeline can support a return to solid growth post-2028. He notes that recent acquisitions funded by COVID-era cash have meaningfully enhanced the company’s R&D portfolio and future earnings power. Furthermore, he sees a disconnect between the market’s expectations and Pfizer’s internal outlook for key commercial assets such as Nurtec and Elrexfio, suggesting current consensus underestimates their revenue potential. Taken together, these elements support his view that Pfizer’s shares are undervalued relative to their long-term growth and margin expansion prospects, justifying his Outperform/Buy recommendation.

According to TipRanks, Seigerman is a 5-star analyst with an average return of 9.4% and a 52.90% success rate. Seigerman covers the Healthcare sector, focusing on stocks such as Bristol-Myers Squibb, Gilead Sciences, and Regeneron.